Expanding the roles for pregnane X receptor in cancer: Proliferation and drug resistance in ovarian cancer

Divya Gupta, Madhukumar Venkatesh, Hongwei Wang, Sean Kim, Michael Sinz, Gary L. Goldberg, Kathleen D. Whitney, Clifford Longley, Sridhar Mani

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Purpose: We examined the presence of the pregnane X receptor (PXR) and its effects on ovarian cancer cells after activation by its cognate ligand. Experimental Design: SKOV-3 and OVCAR-8 ovarian carcinoma cells were analyzed for expression of PXR by quantitative reverse transcription-PCR and Western blot. Human ovarian cancer tissue was also analyzed for PXR expression by immunochemistry. Ligand (agonist)-induced PXR target genes were analyzed in SKOV-3 cells by quantitative reverse transcription-PCR. SKOV-3 cell proliferation was assessed by MTTassay. In vivo confirmation of in vitro effects of PXR ligands were done in NOD.SCID mice carrying SKOV-3 xenografts. Results: PXR is expressed in ovarian cancer cells. In SKOV-3 cells, PXR is functional and its activation by cognate ligands induces PXR target genes (CYP2B6, CYP3A4, and UGT1A1) but not MDR1 and MRP2. PXR activation in SKOV-3 cells induces cell proliferation and drug resistance. In mice harboring SKOV-3 xenografts, rifampicin (PXR agonist) induces cell proliferation and tumor growth. Conclusion: PXR activation, regardless of the type of ligand agonist present, promotes the ''malignant'' phenotype of cancer cells. These data serve as the basis for finding novel nontoxic inhibitors of PXR activation as a method to control cell growth and prevent induction of drug resistance.

Original languageEnglish (US)
Pages (from-to)5332-5340
Number of pages9
JournalClinical Cancer Research
Volume14
Issue number17
DOIs
StatePublished - Sep 1 2008

Fingerprint

Drug Resistance
Ovarian Neoplasms
Neoplasms
Ligands
Cell Proliferation
Heterografts
Reverse Transcription
pregnane X receptor
Immunochemistry
Cytochrome P-450 CYP3A
Polymerase Chain Reaction
SCID Mice
Rifampin
Growth
Genes
Research Design
Western Blotting
Carcinoma
Phenotype

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Expanding the roles for pregnane X receptor in cancer : Proliferation and drug resistance in ovarian cancer. / Gupta, Divya; Venkatesh, Madhukumar; Wang, Hongwei; Kim, Sean; Sinz, Michael; Goldberg, Gary L.; Whitney, Kathleen D.; Longley, Clifford; Mani, Sridhar.

In: Clinical Cancer Research, Vol. 14, No. 17, 01.09.2008, p. 5332-5340.

Research output: Contribution to journalArticle

Gupta, Divya ; Venkatesh, Madhukumar ; Wang, Hongwei ; Kim, Sean ; Sinz, Michael ; Goldberg, Gary L. ; Whitney, Kathleen D. ; Longley, Clifford ; Mani, Sridhar. / Expanding the roles for pregnane X receptor in cancer : Proliferation and drug resistance in ovarian cancer. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 17. pp. 5332-5340.
@article{b0044259c5164b4d9b03b779c809f02d,
title = "Expanding the roles for pregnane X receptor in cancer: Proliferation and drug resistance in ovarian cancer",
abstract = "Purpose: We examined the presence of the pregnane X receptor (PXR) and its effects on ovarian cancer cells after activation by its cognate ligand. Experimental Design: SKOV-3 and OVCAR-8 ovarian carcinoma cells were analyzed for expression of PXR by quantitative reverse transcription-PCR and Western blot. Human ovarian cancer tissue was also analyzed for PXR expression by immunochemistry. Ligand (agonist)-induced PXR target genes were analyzed in SKOV-3 cells by quantitative reverse transcription-PCR. SKOV-3 cell proliferation was assessed by MTTassay. In vivo confirmation of in vitro effects of PXR ligands were done in NOD.SCID mice carrying SKOV-3 xenografts. Results: PXR is expressed in ovarian cancer cells. In SKOV-3 cells, PXR is functional and its activation by cognate ligands induces PXR target genes (CYP2B6, CYP3A4, and UGT1A1) but not MDR1 and MRP2. PXR activation in SKOV-3 cells induces cell proliferation and drug resistance. In mice harboring SKOV-3 xenografts, rifampicin (PXR agonist) induces cell proliferation and tumor growth. Conclusion: PXR activation, regardless of the type of ligand agonist present, promotes the ''malignant'' phenotype of cancer cells. These data serve as the basis for finding novel nontoxic inhibitors of PXR activation as a method to control cell growth and prevent induction of drug resistance.",
author = "Divya Gupta and Madhukumar Venkatesh and Hongwei Wang and Sean Kim and Michael Sinz and Goldberg, {Gary L.} and Whitney, {Kathleen D.} and Clifford Longley and Sridhar Mani",
year = "2008",
month = "9",
day = "1",
doi = "10.1158/1078-0432.CCR-08-1033",
language = "English (US)",
volume = "14",
pages = "5332--5340",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Expanding the roles for pregnane X receptor in cancer

T2 - Proliferation and drug resistance in ovarian cancer

AU - Gupta, Divya

AU - Venkatesh, Madhukumar

AU - Wang, Hongwei

AU - Kim, Sean

AU - Sinz, Michael

AU - Goldberg, Gary L.

AU - Whitney, Kathleen D.

AU - Longley, Clifford

AU - Mani, Sridhar

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Purpose: We examined the presence of the pregnane X receptor (PXR) and its effects on ovarian cancer cells after activation by its cognate ligand. Experimental Design: SKOV-3 and OVCAR-8 ovarian carcinoma cells were analyzed for expression of PXR by quantitative reverse transcription-PCR and Western blot. Human ovarian cancer tissue was also analyzed for PXR expression by immunochemistry. Ligand (agonist)-induced PXR target genes were analyzed in SKOV-3 cells by quantitative reverse transcription-PCR. SKOV-3 cell proliferation was assessed by MTTassay. In vivo confirmation of in vitro effects of PXR ligands were done in NOD.SCID mice carrying SKOV-3 xenografts. Results: PXR is expressed in ovarian cancer cells. In SKOV-3 cells, PXR is functional and its activation by cognate ligands induces PXR target genes (CYP2B6, CYP3A4, and UGT1A1) but not MDR1 and MRP2. PXR activation in SKOV-3 cells induces cell proliferation and drug resistance. In mice harboring SKOV-3 xenografts, rifampicin (PXR agonist) induces cell proliferation and tumor growth. Conclusion: PXR activation, regardless of the type of ligand agonist present, promotes the ''malignant'' phenotype of cancer cells. These data serve as the basis for finding novel nontoxic inhibitors of PXR activation as a method to control cell growth and prevent induction of drug resistance.

AB - Purpose: We examined the presence of the pregnane X receptor (PXR) and its effects on ovarian cancer cells after activation by its cognate ligand. Experimental Design: SKOV-3 and OVCAR-8 ovarian carcinoma cells were analyzed for expression of PXR by quantitative reverse transcription-PCR and Western blot. Human ovarian cancer tissue was also analyzed for PXR expression by immunochemistry. Ligand (agonist)-induced PXR target genes were analyzed in SKOV-3 cells by quantitative reverse transcription-PCR. SKOV-3 cell proliferation was assessed by MTTassay. In vivo confirmation of in vitro effects of PXR ligands were done in NOD.SCID mice carrying SKOV-3 xenografts. Results: PXR is expressed in ovarian cancer cells. In SKOV-3 cells, PXR is functional and its activation by cognate ligands induces PXR target genes (CYP2B6, CYP3A4, and UGT1A1) but not MDR1 and MRP2. PXR activation in SKOV-3 cells induces cell proliferation and drug resistance. In mice harboring SKOV-3 xenografts, rifampicin (PXR agonist) induces cell proliferation and tumor growth. Conclusion: PXR activation, regardless of the type of ligand agonist present, promotes the ''malignant'' phenotype of cancer cells. These data serve as the basis for finding novel nontoxic inhibitors of PXR activation as a method to control cell growth and prevent induction of drug resistance.

UR - http://www.scopus.com/inward/record.url?scp=53049083219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53049083219&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-1033

DO - 10.1158/1078-0432.CCR-08-1033

M3 - Article

C2 - 18765524

AN - SCOPUS:53049083219

VL - 14

SP - 5332

EP - 5340

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 17

ER -